rivastigmine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 65 Diseases   14 Trials   14 Trials   1875 News 


«12...567891011121314151617»
  • ||||||||||  rivastigmine / generics
    Preclinical, Journal:  Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model. (Pubmed Central) -  Mar 29, 2019   
    Moreover, rivastigmine demonstrated a P-gp expression dependent neuroprotective effect that was highest in APP(+)/mdr1(+/+)>APP(+)/mdr1(+/-)>APP(+)/mdr1(-/-) as determined by expression of synaptic markers PSD-95 and SNAP-25 using Western blot analysis. Collectively, our results suggest that P-gp plays important role in mediating rivastigmine non-cholinergic beneficial effects, including Aβ brain load reduction, neuroprotective and anti-inflammatory effects in the AD mouse models.
  • ||||||||||  donepezil / generics, galantamine hydrobromide / generics, rivastigmine / generics
    Clinical, Journal:  Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease. (Pubmed Central) -  Mar 29, 2019   
    The present study suggests that despite a relatively lower dose of ChEI after the switch, switching from donepezil or rivastigmine preserved cognitive functions for at least 6 M. Switching from galantamine to rivastigmine improved Mini-Mental State Examination and ABS at 3 M, but did not improve ADL scores. Geriatr Gerontol Int 2017; 17: 1843-1848.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Enrollment change, Trial completion date, Trial primary completion date:  Masitinib in Patients With Mild to Moderate Alzheimer's Disease (clinicaltrials.gov) -  Dec 5, 2018   
    P3,  N=721, Active, not recruiting, 
    Geriatr Gerontol Int 2017; 17: 1991-1999. N=396 --> 721 | Trial completion date: Dec 2016 --> Oct 2019 | Trial primary completion date: Dec 2015 --> Apr 2019
  • ||||||||||  rivastigmine / Generic mfg.
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  CHEVAL: Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease (clinicaltrials.gov) -  Oct 10, 2018   
    P4,  N=91, Terminated, 
    N=396 --> 721 | Trial completion date: Dec 2016 --> Oct 2019 | Trial primary completion date: Dec 2015 --> Apr 2019 N=168 --> 91 | Trial completion date: Dec 2022 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Sep 2018; enrollment to slow, insufficient funds
  • ||||||||||  donepezil / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date:  Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly (clinicaltrials.gov) -  Jun 13, 2018   
    P4,  N=170, Active, not recruiting, 
    N=168 --> 91 | Trial completion date: Dec 2022 --> Sep 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Sep 2018; enrollment to slow, insufficient funds Recruiting --> Active, not recruiting | Trial completion date: May 2018 --> May 2019 | Trial primary completion date: May 2018 --> May 2019
  • ||||||||||  Enrollment change, Trial termination, Trial primary completion date, Adverse events:  Pharmacovigilance in Gerontopsychiatric Patients (clinicaltrials.gov) -  Oct 19, 2017   
    P3,  N=407, Terminated, 
    Trial primary completion date: Dec 2019 --> Dec 2021 N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017
  • ||||||||||  rivastigmine / Generic mfg.
    Trial completion:  Rivastigmine Capsules in Patients With Probable Vascular Dementia (clinicaltrials.gov) -  Mar 27, 2017   
    P3,  N=521, Completed, 
    N=2000 --> 407 | Recruiting --> Terminated | Trial primary completion date: Feb 2017 --> Jun 2017 No longer recruiting --> Completed
  • ||||||||||  Ergonex (ergotamine/caffeine) / AC Farma
    Phase classification, Enrollment change:  Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) -  Jan 18, 2017   
    P1,  N=389, Completed, 
    No longer recruiting --> Completed Phase classification: P3 --> P1 | N=80 --> 389
  • ||||||||||  rivastigmine / Generic mfg., duloxetine / Generic mfg.
    Enrollment open:  Quality Improvement and Practice Based Research in Neurology Using the EMR (clinicaltrials.gov) -  Jan 18, 2017   
    P4,  N=3300, Enrolling by invitation, 
    Phase classification: P3 --> P1 | N=80 --> 389 Not yet recruiting --> Enrolling by invitation
  • ||||||||||  Ergonex (ergotamine/caffeine) / AC Farma
    Trial completion, Enrollment change, Trial primary completion date:  Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) -  Jan 17, 2017   
    P3,  N=80, Completed, 
    Not yet recruiting --> Enrolling by invitation Recruiting --> Completed | N=500 --> 80 | Trial primary completion date: Apr 2017 --> Jan 2017
  • ||||||||||  Ergonex (ergotamine/caffeine) / AC Farma
    Trial primary completion date:  Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) -  Apr 28, 2016   
    P3,  N=500, Recruiting, 
    Recruiting --> Completed Trial primary completion date: Apr 2016 --> Apr 2017
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Enrollment change, Trial termination, HEOR:  COMET-AD: Comparative Research of Alzheimer's Disease Drugs (clinicaltrials.gov) -  Apr 14, 2016   
    P=N/A,  N=200, Terminated, 
    The trial was terminated at Stage 1; did not proceed to Stage 2. N=300 --> 200 | Active, not recruiting --> Terminated; Low study accrual caused the study to be ended early.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Trial completion, Enrollment change, Trial primary completion date, Adverse events:  A Genetic and Perfusion Study of Response to Cognitive Enhancers in Lewy Body Disease (clinicaltrials.gov) -  Apr 14, 2016   
    P=N/A,  N=57, Completed, 
    N=300 --> 200 | Active, not recruiting --> Terminated; Low study accrual caused the study to be ended early. Recruiting --> Completed | N=180 --> 57 | Trial primary completion date: Dec 2018 --> Jan 2016
  • ||||||||||  Ergonex (ergotamine/caffeine) / AC Farma
    Trial primary completion date:  Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) -  Jun 11, 2015   
    P3,  N=500, Recruiting, 
    Active, not recruiting --> Completed Trial primary completion date: May 2015 --> Apr 2016
  • ||||||||||  rivastigmine / Generic mfg.
    Enrollment closed:  Brain Changes by Rivastigmine According to Butyrylcholinesterase Alleles (clinicaltrials.gov) -  May 14, 2015   
    P=N/A,  N=70, Active, not recruiting, 
    Trial primary completion date: May 2015 --> Apr 2016 Not yet recruiting --> Active, not recruiting
  • ||||||||||  rivastigmine / Generic mfg.
    Trial completion, Trial primary completion date:  Rivastigmine and Huperzine A as Treatments for Cocaine Dependence (clinicaltrials.gov) -  Jan 28, 2015   
    P1,  N=72, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | Trial primary completion date: May 2013 --> Jun 2014
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Enrollment closed, Trial primary completion date, HEOR:  COMET-AD: Comparative Research of Alzheimer's Disease Drugs (clinicaltrials.gov) -  Dec 17, 2014   
    P=N/A,  N=300, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Initiation date: Aug 2013 --> Nov 2013 | Trial primary completion date: Aug 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Oct 2015
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., rivastigmine / Generic mfg.
    Enrollment closed:  Discontinuation of Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease (clinicaltrials.gov) -  Nov 19, 2014   
    P3,  N=50, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2013 --> Oct 2015 Recruiting --> Active, not recruiting
  • ||||||||||  Ergonex (ergotamine/caffeine) / AC Farma
    Trial primary completion date:  Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) -  May 1, 2014   
    P3,  N=500, Recruiting, 
    Trial completion date: Sep 2014 --> May 2015 Trial primary completion date: May 2014 --> May 2015
  • ||||||||||  Ergonex (ergotamine/caffeine) / AC Farma
    Trial completion date:  Treatment of Orthostatic Hypotension in Autonomic Failure (clinicaltrials.gov) -  May 1, 2014   
    P3,  N=500, Recruiting, 
    Trial primary completion date: May 2014 --> May 2015 Trial completion date: May 2014 --> May 2016